<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110664</url>
  </required_header>
  <id_info>
    <org_study_id>142589</org_study_id>
    <nct_id>NCT05110664</nct_id>
  </id_info>
  <brief_title>APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE</brief_title>
  <acronym>APPETITE</acronym>
  <official_title>A Double-blind, Cross-over, Placebo-controlled, Proof-of-concept Study Using Oral Peptide YY3-36 Solution to Investigate the Mechanistic Role of Lingual PYY in Regulating Appetite, Energy Intake and Food Preference in People With Overweight/Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gila Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, cross-over, placebo-controlled, proof-of-concept study using oral peptide&#xD;
      YY3-36 solution to investigate the mechanistic role of lingual PYY in regulating appetite,&#xD;
      energy intake and food preference in people with overweight/obesity. The aim of this study is&#xD;
      to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and&#xD;
      food preference in people with overweight/obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to address the study objective two independent investigations in two separate groups&#xD;
      of participants will need to be undertaken, to avoid cross-contamination of the results.&#xD;
&#xD;
        1. Cohort/Investigation 1: A randomised within-subject double-blind cross-over&#xD;
           placebo-controlled study to investigate the role of lingual PYY in regulating fasted and&#xD;
           post-meal appetite following a fixed energy intake meal.&#xD;
&#xD;
        2. Cohort/Investigation 2: A randomised within-subject double-blind cross-over&#xD;
           placebo-controlled study to investigate the role of lingual PYY in regulating ad libitum&#xD;
           energy intake and food preference.&#xD;
&#xD;
      People with overweight or obesity (BMI 25.0-39.9 kg/m2), identified via the University&#xD;
      College London Hospitals (UCLH) Bariatric Centre for Weight Management and Metabolic Surgery&#xD;
      and through advertising via University College London (UCL) and ULCH, will be invited to take&#xD;
      part.&#xD;
&#xD;
      Potential participants will initially attend a screening visit, where informed, written&#xD;
      consent will first be taken. During the screening visit, medical, drug and dietary histories&#xD;
      will be taken and participant eligibility will be confirmed.&#xD;
&#xD;
      Participants will attend on two separate occasions at least 7 days apart for both&#xD;
      cohort/investigation 1 and cohort/investigation 2. 20 participants per cohort/investigation&#xD;
      will be randomised (in a 1:1 manner), stratified by sex, to receive either oral PYY3-36&#xD;
      solution or matched placebo at their first study visit. Participants will be recruited onto&#xD;
      study/investigation 1 first and once this is complete, new subjects will be enrolled onto&#xD;
      study/investigation 2.&#xD;
&#xD;
      Cohort/Intervention 1: The day prior to each visit participants will complete a 24 hour food&#xD;
      diary and appetite scores at home. Participants will fast overnight (12 hours) and consume&#xD;
      only water until reaching the clinical facility the following morning. Participants will need&#xD;
      to refrain from exercise for 2 days prior to the study visits and from drinking alcohol. On&#xD;
      arrival, medical history will be re-reviewed, sociodemographic information collected and a&#xD;
      pregnancy test for women of childbearing potential will be performed. Body weight and&#xD;
      composition will be measured. Baseline assessments of fasted subjective appetite assessed&#xD;
      using validated visual analogue scales (VAS), saliva PYY levels (via saliva sample) and&#xD;
      circulating gut hormones (via blood sample) will be taken.&#xD;
&#xD;
      A single dose of lingual PYY (GT-001) or placebo will be administered. Appetite scores and a&#xD;
      paired blood and saliva sample will be collected 10-15 minutes later. 30 minutes after study&#xD;
      drug application, participants will then be asked to consume a standardised fixed meal over&#xD;
      15 minutes using established protocol and appetite scores (VAS) and saliva and blood samples&#xD;
      will be taken for 180 minutes post-meal at regular intervals. Participants will be asked to&#xD;
      complete 24-hour food diary and appetite scores 6, 12 and 24 hours after the study visit.&#xD;
&#xD;
      Cohort/Intervention 2: The day prior to each study visit participants will complete a 24-hour&#xD;
      food diary and appetite scores at home. Participants will fast overnight (12 hours) and&#xD;
      consume only water until reaching the clinical facility the following morning. Participants&#xD;
      will need to refrain from exercise for 2 days prior to the study visits and from drinking&#xD;
      alcohol. On arrival, medical history will be re-reviewed, sociodemographic information&#xD;
      collected and a pregnancy test for women of childbearing potential will be performed. Body&#xD;
      weight and composition will be measured. Baseline assessments of fasted subjective appetite&#xD;
      assessed using validated VAS, saliva PYY levels (via saliva sample) and circulating gut&#xD;
      hormones (via blood sample) will be taken.&#xD;
&#xD;
      A single dose of lingual PYY (GT-001) or placebo will be administered. Appetite scores and a&#xD;
      paired blood and saliva sample will be collected 10-15 minutes later. 30 minutes after study&#xD;
      drug application, participants will be offered an extensive free-choice buffet lunch and&#xD;
      asked to eat until full. Ad libitum energy intake and food preferences will be assessed.&#xD;
      Participants will be asked to rank likeness of the items of the buffet. Appetite scores (VAS)&#xD;
      and paired blood and saliva sample will be taken again 60 minutes from the onset of the meal.&#xD;
      Participants will be asked to complete 24-hour food diary and appetite scores 24 hours after&#xD;
      the study visit.&#xD;
&#xD;
      After a 7-day washout period participants in each cohort/intervention will be crossed-over&#xD;
      and the same visit will be repeated. Both the participants and researchers will be blinded to&#xD;
      the study condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>appetite scores</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>area-under-the curve for appetite scores. Not indicative of either bad or worse outcome, just subjective indication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>energy intake expressed as Kcal of eaten food</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>ad libitum energy intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PYY levels</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Area-under-the-curve for saliva PYY levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut hormones levels</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Area-under-the-curve for gut hormones levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-h energy intake</measure>
    <time_frame>24 hours after study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h appetite</measure>
    <time_frame>24 hours after study visit</time_frame>
    <description>Subjective appetite scores for 24 hours following a fixed meal using VAS - a 1 to 10 scale will be used where the higher the score the higher the level of feeling of the item for the subject. No better or worse meaning applied a priory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macronutrient selection</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Macronutrient content of consumed food during ad libitum meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>food preference using labelled magnitude scales (LMS)</measure>
    <time_frame>through study completion, an average of 6 hours</time_frame>
    <description>labelled magnitude scales (LMS) for components of the ad libitum meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>food preference questionnaire (FPQ)</measure>
    <time_frame>once, at beginning of study visit</time_frame>
    <description>The food preference questionnaire requires participants to rate their liking of 62 individual foods on a 5-point Likert scale, ranging from &quot;not at all&quot; to &quot;a lot&quot;. A higher score indicative of greater liking of a food.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Cohort/Intervention 1</arm_group_label>
    <description>Meal test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort/Intervention 2</arm_group_label>
    <description>Ad libitum meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PYY (3-36) Peptide</intervention_name>
    <description>oral PYY3-36 solution</description>
    <arm_group_label>Cohort/Intervention 1</arm_group_label>
    <arm_group_label>Cohort/Intervention 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placibo</intervention_name>
    <description>oral placebo solution</description>
    <arm_group_label>Cohort/Intervention 1</arm_group_label>
    <arm_group_label>Cohort/Intervention 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with overweight or obesity (BMI 25.0-39.9 kg/m2), identified via the University&#xD;
        College London Hospitals (UCLH) Bariatric Centre for Weight Management and Metabolic&#xD;
        Surgery and through advertising via University College London (UCL) and ULCH, will be&#xD;
        invited to take part.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Adults aged 18-65 inclusive. 2. People with a body mass index (BMI) between 25.0&#xD;
             and 39.9 kg/m2 3. Stable weight for past 3 months (â‰¤5% change in preceding 3 months as&#xD;
             reported by participants).&#xD;
&#xD;
             4. Females of childbearing potential must be on highly effective contraception and&#xD;
             have a negative pregnancy test within 7 days of their study visits. NOTE: Subjects are&#xD;
             considered not of childbearing potential if they are surgically sterile (i.e. they&#xD;
             have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or&#xD;
             they are postmenopausal.&#xD;
&#xD;
             5. Fluent in English and able to understand and complete questionnaires. 6. Willing&#xD;
             and able to provide written informed consent and comply with the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant or breast-feeding.&#xD;
&#xD;
          2. Female subjects of childbearing potential who are not on highly effective&#xD;
             contraception.&#xD;
&#xD;
          3. Post-menopausal women who have not had a period of spontaneous amenorrhea for more&#xD;
             than 1 year.&#xD;
&#xD;
          4. Previous bariatric surgery.&#xD;
&#xD;
          5. Type 1 or 2 diabetes.&#xD;
&#xD;
          6. Current use of weight loss medications or taking medication that affects appetite,&#xD;
             e.g., antidepressants such as mirtazapine.&#xD;
&#xD;
          7. Food intolerances, or allergies, that would make fixed energy meal and/or ad libitum&#xD;
             meal unable to be performed.&#xD;
&#xD;
          8. Impairment of sense of taste and/or smell, as per subject assessment and direct&#xD;
             questioning.&#xD;
&#xD;
          9. Poor dental hygiene or oral pathology.&#xD;
&#xD;
         10. Current smokers of tobacco products.&#xD;
&#xD;
         11. Any other factor making the participant unsuitable in the view of investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Rachel L Batterham</last_name>
    <phone>02076790991</phone>
    <phone_ext>40991</phone_ext>
    <email>r.batterham@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alisia Carnemolla, PhD</last_name>
    <phone>02076796308</phone>
    <phone_ext>46308</phone_ext>
    <email>a.carnemolla@ucl.ac.uk</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>appetite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

